Voxtalisib is primarily investigated for its potential in cancer treatment, particularly as a dual inhibitor of PI3K and mTOR pathways. These pathways are often dysregulated in various cancers, making Voxtalisib a promising candidate for targeted therapy. It is studied in clinical trials for its efficacy in treating solid tumors, including breast, lung, and ovarian cancers. By inhibiting these pathways, Voxtalisib aims to disrupt cancer cell growth, survival, and proliferation. Additionally, it is explored in combination therapies to enhance the effectiveness of other anticancer agents, potentially overcoming drug resistance in certain cancers.